METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Active, not recruiting · NCT05504252 · Registry updated 2026-01-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, colorectal adenocarcinoma, cystic, mucinous, and serous neoplasm, epithelial neoplasm, mucinous adenocarcinoma, neoplasm, signet ring cell carcinoma | Active, not recruiting | Phase 2 | 2026-01-07 | NCT05504252 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Oslo University Hospital | 327 |
| St. Olavs Hospital | 167 |
| University Hospital, Akershus | 87 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Akershus University Hospital | Lørenskog | Norway | 9 |
| Oslo University Hospital | Oslo | Norway | 1 |
| St Olavs Hospital | Trondheim | Norway | 1 |